Paradigm Biopharmaceuticals Ltd has released a press release.
Appendix 4E and 2025 Annual Report
Filed with ASX ·
6ix hasn’t read this filing yet.
Paradigm Biopharmaceuticals Ltd. on 6ix
Story so far
Earlier from Paradigm Biopharmaceuticals
- June 2025 Quarterly Activities Report & Appendix 4C
- Paradigm Secures US$27M to Advance Phase 3 OA Trial
- Paradigm Strengthens OA Pipeline with Strategic Acquisition
- PAR Receives US Ethics Approval for Phase 3
- March 2025 Quarterly Activities Report & Appendix 4C
Later from Paradigm Biopharmaceuticals
- Phase 3 Knee OA Trial Recruiting and Dosing in AUS & US
- September 2025 Quarterly Activities Report & Appendix 4C
- Drawdown of Tranche 2 under the Convertible Note Facility
- Phase 3 Knee OA Trial Recruitment Update
- iPPS Phase 2 Biomarker Results Published in Leading Journal
Follow Paradigm Biopharmaceuticals into a list and get an email when it puts out news.
Follow Paradigm Biopharmaceuticals